NCT05929989

Brief Summary

to detect role of cystatin D and fibrinogen like protein 1 in rheumatoid arthritis asses relationship between disease activity and cystatin D and fibrinogen like protein 1

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
86

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 5, 2023

Completed
6 months until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

July 5, 2023

Status Verified

June 1, 2023

Enrollment Period

2 years

First QC Date

June 26, 2023

Last Update Submit

June 26, 2023

Conditions

Fibrinogen Like Protein 1

Outcome Measures

Primary Outcomes (1)

  • detect role of cystatin D and fibrinogen like protein 1

    detect role of the two biomarkers and there relationship to rheumatoid arthriths

    one year

Study Arms (2)

active disease

Diagnostic Test: ELISA TEST

control

Diagnostic Test: ELISA TEST

Interventions

ELISA TESTDIAGNOSTIC_TEST

ELISA TEST for cystatin D and fibrinogen like protein

active diseasecontrol

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adult patient diagnosed with rheumatoid arthrits

You may qualify if:

  • adult patient diagnosed for rheumatoid arthritis

You may not qualify if:

  • patient with overlap syndrome indiviuals with other auto immune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Lin WW, Ho KW, Su HH, Fang TF, Tzou SC, Chen IJ, Lu YC, Chang MS, Tsai YC, Liu ES, Su YC, Wang YT, Cheng TL, Huang HK. Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice. Front Immunol. 2021 Dec 16;12:767868. doi: 10.3389/fimmu.2021.767868. eCollection 2021.

    PMID: 34975855BACKGROUND

  • Scherer HU, Haupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020 Jun;110:102400. doi: 10.1016/j.jaut.2019.102400. Epub 2020 Jan 22.

    PMID: 31980337RESULT

Central Study Contacts

heba abdelsalam selim

CONTACT

00201222260723hebaselim85@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr

Study Record Dates

First Submitted

June 26, 2023

First Posted

July 5, 2023

Study Start

January 1, 2024

Primary Completion

January 1, 2026

Study Completion

January 1, 2026

Last Updated

July 5, 2023

Record last verified: 2023-06